R^1 is Tyr or His,

R^2 is D-Arg or D-Cit,

R^5 is Ile or Val,

R^6 is Phe, Nal or Phe(Y), in which Y=F, Cl, Br,

R^8 is Asn, Gln, Ser, Thr, Ala, D-Asn, D-Gln, D-Ser, D-Thr, Abu, D-Abu, or Aib,

R^9 is Arg, Har, Lys, Orn, D-Arg, D-Har, D-Lys, D-Orn, Cit, Nle, Tyr (Me), Ser, Ala or Aib,

R^{10} is Tyr or Phe(Y), in which Y=H, F, Cl, Br, or OCH_3,

R^{12} is Lys, D-Lys, or Orn,

R^{13} is Val or Nle,

R^{14} is Leu or Nle,

R^{15} is Gly, Ala, Abu, Nle or Gln,

R^{16} is Gln or Arg,

R^{18} is Ser or Nle,

R^{19} is Ala or Abu,

R^{21} is Lys or Orn,

R^{22} is Leu, Ala or Aib,

R^{27} is Met, Leu, Nle, Abu, or D-Arg,

R^{28} is Arg, D-Arg, Ser, Asn, Asp, Ala or Abu,

R^{29} is Arg, D-Arg, Har or D-Har,

and pharmaceutically acceptable salts thereof.

10. (Amended) A[a] method of treating a patient having a cancer carrying receptors for IGF-I or –II which comprises administering to said patient an effective amount of a [compound of claim 1] peptide selected from the group having the formulae:

X-R^1-R^2-Asp-Ala-R^5-R^6-Thr-R^8-R^9-R^{10}-Arg-R^{12}-R^{13}-R^{14}-R^{15}-R^{16}-Leu-R^{18}-R^{19}-Arg-R^{21}-R^{22}-Leu-Gln-Asp-Ile-R^{27}-R^{28}-R^{29}-NH_2

wherein X is PhAc, IndAc, Ibu, Nac, 1- or 2-Npr, or Fpr,

R^1 is Tyr or His,

R^2 is D-Arg or D-Cit,

R^5 is Ile or Val,

R^6 is Phe, Nal or Phe(Y), in which Y=F, Cl, Br,

R^8 is Asn, Gln, Ser, Thr, Ala, D-Asn, D-Gln, D-Ser, D-Thr, Abu, D-Abu, or Aib,

R^9 is Arg, Har, Lys, Orn, D-Arg, D-Har, D-Lys, D-Orn, Cit, Nle, Tyr (Me), Ser, Ala or Aib,

R^{10} is Tyr or Phe(Y), in which Y=H, F, Cl, Br, or OCH_3,

R^{12} is Lys, D-Lys, or Orn,

R^{13} is Val or Nle,

R^{14} is Leu or Nle,

R^{15} is Gly, Ala, Abu, Nle or Gln,

R^{16} is Gln or Arg,

R^{18} is Ser or Nle,

R^{19} is Ala or Abu,

R^{21} is Lys or Orn,

R^{22} is Leu, Ala or Aib,

R^{27} is Met, Leu, Nle, Abu, or D-Arg,

R^{28} is Arg, D-Arg, Ser, Asn, Asp, Ala or Abu,

R^{29} is Arg, D-Arg, Har or D-Har,

and pharmaceutically acceptable salts thereof.

11. (Amended) A[a] a method for inhibiting IGF-II levels in tumors (cancers) and the expression of mRNA for IGF-II in the same tumors, which comprises administering to said patient an effective amount of [a compound of Claim 1] a peptide selected from the group having the formulae:

X-R^1-R^2-Asp-Ala-R^5-R^6-Thr-R^8-R^9-R^{10}-Arg-R^{12}-R^{13}-R^{14}-R^{15}-R^{16}-Leu-R^{18}-R^{19}-Arg-R^{21}-R^{22}-Leu-Gln-Asp-Ile-R^{27}-R^{28}-R^{29}-NH_2

wherein X is PhAc, IndAc, Ibu, Nac, 1- or 2-Npr, or Fpr,

R^1 is Tyr or His,

R^2 is D-Arg or D-Cit,

R^5 is Ile or Val,

R^6 is Phe, Nal or Phe(Y), in which Y=F, Cl, Br,

R^8 is Asn, Gln, Ser, Thr, Ala, D-Asn, D-Gln, D-Ser, D-Thr, Abu, D-Abu, or Aib,

R^9 is Arg, Har, Lys, Orn, D-Arg, D-Har, D-Lys, D-Orn, Cit, Nle, Tyr (Me), Ser, Ala or Aib,

R^{10} is Tyr or Phe(Y), in which Y=H, F, Cl, Br, or OCH_3,

R^{12} is Lys, D-Lys, or Orn,

R^{13} is Val or Nle,

R^{14} is Leu or Nle,

R^{15} is Gly, Ala, Abu, Nle or Gln,

R^{16} is Gln or Arg,

R^{18} is Ser or Nle,

R^{19} is Ala or Abu,

R^{21} is Lys or Orn,

R^{22} is Leu, Ala or Aib,

R^{27} is Met, Leu, Nle, Abu, or D-Arg,

R^{28} is Arg, D-Arg, Ser, Asn, Asp, Ala or Abu

R^{29} is Arg, D-Arg, Har or D-Har,

and pharmaceutically acceptable salts thereof.

Respectfully submitted,

Omri M. Behr

Regis. No. 22,940

Tele: 732-494-5240

Shal31c12.plm